ETV2 and lymphangioleiomyomatosis: Hence, targeting ETV2, with its potential for cytocidal cellular responses in Tsc2-deficient cells, might offer a therapeutic advantage in LAM over rapalogs alone, which primarily act as cytostatic drugs.